It was a pleasure to be able to speak with Prof. Dedee Murrell (St George Hospital, University of New South Wales, Sydney, Australia) about the BELIEVE Phase 2 (Part A) Study (NCT02704429) which investigated the oral BTK inhibitor, rilzabrutinib, in pemphigus.
Her abstract entitled ‘Treatment With Rilzabrutinib Results in Rapid and Significant Decrease in Steroid Use and Improved Quality of Life in Patients With Chronic Relapsing Pemphigus: BELIEVE Phase II Study (Part A)’ was presented at the AAD VMX, 23-25 April 2021.
- What is the rationale for the use of BTK inhibitors in pemphigus? (0:05)
- What were the aims, design and patient population of the BELIEVE study? (0:51)
- What were the efficacy and quality of life endpoints of the study and how well were these achieved? (2:10)
- What were the safety and tolerability findings of the study? (3:18)
- What future studies are planned? (4:14)
Disclosures: Prof. Dedee Murrell has acted and an investigator and advisor for Principia-Sanofi, ArgenX, Roche-Genentech and Eli Lilly. Prof. Murrell is also the co-inventor of the PDAI and ABQOL measures.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the AAD VMX 2021.
Share this Video
Related Videos In Dermatological Conditions
Christian Vestergaard, EADV 2021: Biologics for Paediatric Skin Diseases
It was a pleasure to meet Dr Christian Vestergaard (Aarhus University Hospital, Aarhus, Denmark) to discuss the use of biologics in the treatment of paediatric skin diseases. His presentation entitled ‘The use of biological drugs for skin diseases in children’ was presented at the EADV 30th Congress, 29 Sep – 2 Oct 2021. Questions What […]
Rosalie Luiten, EADV 2021: The Role of Resident Memory T-cells in Vitiligo and Tumour Immunity
touchIMMUNOLOGY were delighted to discuss with Prof. Rosalie Luiten (University of Amsterdam, Amsterdam, The Netherlands) the role of resident memory T cells in autoimmune vitiligo and tumour immunity, and how they could be used as a therapeutic target. Her presentation entitled ‘Skin-resident T-cells as a potential new therapeutic target in vitiligo’ was given at the […]
Rosalie Luiten, EADV 2021: The Link between Vitiligo and Melanoma
It was a pleasure to discuss with Prof. Rosalie Luiten (University of Amsterdam, Amsterdam, The Netherlands) the immunological link between vitiligo and melanoma. Her presentation entitled ‘Skin-resident T-cells as a potential new therapeutic target in vitiligo’ was given at the EADV 30th Congress, 29 Sep – 2 Oct. Questions How are vitiligo and melanoma linked? […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!